Sanpromeda, UAB - financials and debts

Company age: 20 y. 7 mo.

Update

Sanpromeda - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 195,837 224,245 248,452 217,996 269,562 412,746 436,807 276,801
Profit before tax - - - - -5,664 12,887 18,190 -32,443
Net profit 3,220 16,250 2,079 1,480 -5,664 11,774 15,544 -32,443
Equity 29,912 46,162 48,241 49,720 44,057 55,831 71,374 38,931
Liabilities 25,842 41,653 33,197 19,450 59,659 50,033 46,462 43,311
Non-current assets 290 290 290 290 290 290 290 290
Current assets 55,464 87,525 81,148 68,880 103,426 105,423 117,546 81,952
Total assets 55,754 87,815 81,438 69,170 103,716 105,713 117,836 82,242
Taxes paid
STI taxes - - - - - 92,997 105,623 75,589
Social insurance contributions - - - - - 14,365 14,715 -
Financial indicators
Revenue change y/y -3.0% +14.5% +10.8% -12.3% +23.7% +53.1% +5.8% -36.6%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 5.8% 18.5% 2.6% 2.1% -5.5% 11.1% 13.2% -39.4%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 10.8% 35.2% 4.3% 3.0% -12.9% 21.1% 21.8% -83.3%
Profit margin Net profit margin. Shows the overall profitability of the company. 1.6% 7.2% 0.8% 0.7% -2.1% 2.9% 3.6% -11.7%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. - - - - -2.1% 3.1% 4.2% -11.7%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.9 0.9 0.7 0.4 1.4 0.9 0.7 1.1
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 33,572 46,396 62,113 54,499 67,391 103,187 111,524 92,267

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Sanpromeda - Social security debts

From To Debt, €
2024-11-18 2024-12-03 1.53
2024-10-16 2024-11-04 1.53
2024-09-17 2024-10-02 1.53
2024-08-19 2024-09-02 1.53
2024-07-16 2024-08-04 1.53
2024-06-18 2024-07-01 1.53
2024-05-16 2024-06-06 1.53
2024-04-23 2024-05-02 1.53
2024-03-27 2024-03-27 93.74
2024-03-18 2024-03-26 99.70
2024-02-19 2024-03-04 99.70
2024-01-16 2024-02-04 99.70

Sanpromeda - VMI tax arrears

From To Overdue, €
2026-01-20 2026-01-20 0.19
2026-01-14 2026-01-19 35.99

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Sanpromeda, UAB (code 300535059) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €276.8K, down 36.6% year on year and 32.9% compared with 2023. After two profitable years, net profit turned to a loss of €32.4K in 2025, while profit margin deteriorated to -11.7% from 3.6% in 2024 and 2.9% in 2023. The 2024 results showed revenue of €436.8K and net profit of €15.5K, which marked the best performance in the three-year period. The balance sheet weakened in 2025 as total assets declined to €82.2K from €117.8K a year earlier, equity fell to €38.9K, and liabilities stood at €43.3K. The equity ratio was 47.3% and debt-to-equity was 1.11. Asset turnover reached 3.37x, indicating relatively efficient use of assets in revenue generation despite the weaker results. Revenue per employee was €92.3K, while profit per employee was -€10.8K in 2025.